When archives collide: managing eComms risk in pharma M&A

Communications data: the blind spot in M&A due diligence The most expensive skeletons in a biopharmaceutical M&A aren’t hiding in the IP portfolio or the clinical trial data. They’re sitting in a WhatsApp thread nobody thought to audit. Biopharma dealmaking is accelerating as the upcoming ‘patent cliff’ nears, a term coined to describe the sudden… Continue reading When archives collide: managing eComms risk in pharma M&A